Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017094805) METHOD FOR EVALUATING EFFICACY OF TREATMENT FOR MALIGNANT NEOPLASM BY MEASURING AMOUNT OF CTDNA
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/094805 International Application No.: PCT/JP2016/085638
Publication Date: 08.06.2017 International Filing Date: 30.11.2016
IPC:
C12Q 1/68 (2006.01) ,C12Q 1/06 (2006.01) ,G01N 33/48 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
02
involving viable micro-organisms
04
Determining presence or kind of micro-organism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
06
Quantitative determination
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
Applicants:
株式会社DNAチップ研究所 DNA CHIP RESEARCH INC. [JP/JP]; 神奈川県横浜市鶴見区末広町一丁目1番地43 1-1-43, Suehirocho, Tsurumi-ku, Yokohama-shi, Kanagawa 2300045, JP
地方独立行政法人 大阪府立病院機構 OSAKA PREFECTURAL HOSPITAL ORGANIZATION [JP/JP]; 大阪府大阪市住吉区万代東3丁目1番56号 3-1-56, Bandaihigashi, Sumiyoshi-ku, Osaka-shi, Osaka 5580056, JP
Inventors:
加藤 菊也 KATO, Kikuya; JP
今村 文生 IMAMURA, Fumio; JP
内田 純二 UCHIDA, Junji; JP
久木田 洋児 KUKITA, Yoji; JP
西野 和美 NISHINO, Kazumi; JP
熊谷 融 KUMAGAI, Toru; JP
Agent:
矢口 太郎 YAGUCHI, Taro; JP
Priority Data:
62/260,97330.11.2015US
Title (EN) METHOD FOR EVALUATING EFFICACY OF TREATMENT FOR MALIGNANT NEOPLASM BY MEASURING AMOUNT OF CTDNA
(FR) PROCÉDÉ D’ÉVALUATION DE L'EFFICACITÉ D'UN TRAITEMENT DE TUMEUR MALIGNE PAR MESURE DE LA QUANTITÉ D’ADNCT
(JA) ctDNA量の測定による悪性新生物に対する治療の効果を評価する方法
Abstract:
(EN) [Problem] To provide a method for evaluating the efficacy of treatment for malignant neoplasm in a subject by measuring the amount of ctDNA in the subject. [Solution] A method for evaluating efficacy of treatment for malignant neoplasm in a subject, the method having (a) a step for measuring the amount of ctDNA in blood originating from the subject prior to the start of the treatment for malignant neoplasm, (b) a step for measuring the amount of ctDNA in blood originating from the subject after the start of the treatment for malignant neoplasm, and (c) a step for dividing the value obtained in step b by the value obtained in step a.
(FR) Le problème décrit par la présente invention porte sur un procédé d’évaluation de l'efficacité d'un traitement de tumeur maligne par mesure de la quantité d’ADNct. La solution de la présente invention consiste en un procédé d’évaluation de l'efficacité d'un traitement de tumeur maligne chez un sujet, le procédé comprenant (a) une étape de mesure de la quantité d’ADNct dans le sang du sujet avant le début du traitement de la tumeur maligne, (b) une étape de mesure de la quantité d’ADNct dans le sang du sujet après le début du traitement de la tumeur maligne, et (c) une étape de division de la valeur obtenue dans l'étape b par la valeur obtenue dans l'étape a.
(JA) 【課題】 被験者におけるctDNA量を測定することにより、当該被験者における悪性新生物に対する治療の効果を評価する方法を提供すること。 【解決手段】 被験者における悪性新生物に対する治療の効果を評価する方法であって、(a)悪性新生物に対する当該治療開始前の前記被験者由来の血液中のctDNA量を測定する工程と、(b)悪性新生物に対する当該治療開始後の前記被験者由来の血液中のctDNA量を測定する工程と、(c)工程bで得た値を、工程aで得た値で除算する工程と、を有する、方法。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
EP3385391